Literature DB >> 23795882

Predictors of diabetes mellitus and abnormal blood glucose in patients receiving opioid maintenance treatment.

Ayman Fareed1, Johnita Byrd-Sellers, Sreedevi Vayalapalli, Karen Drexler, Lawrence Phillips.   

Abstract

BACKGROUND: Buprenorphine is a partial opioid agonist and may have less impact on the risk of developing diabetes mellitus (DM) compared to full opioid agonists like methadone.
METHODS: We conducted an observational retrospective study to investigate the predictable factors for impaired glucose tolerance and predisposition to DM in two groups of opiate addicts receiving long-term methadone maintenance treatment (MMT) [n = 58] or buprenorphine maintenance treatment (BMT) [n = 61].
RESULTS: In our cohort, being African American, hepatitis C positive status, elevated AST, and ALT, and being on methadone were significantly correlated to being diagnosed with DM. Among all those factors, being on methadone was most significantly related to being diagnosed with DM (χ² = 3.9888, p-value = .0458). The BMI was the only factor that was significantly correlated to having abnormal A1c level (χ² = 6.4229, p-value = .0113).
CONCLUSIONS: Buprenorphine may be less likely to contribute to the development of DM than methadone. More research is needed to understand the link between opioids and DM.
Copyright © American Academy of Addiction Psychiatry.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23795882     DOI: 10.1111/j.1521-0391.2013.12043.x

Source DB:  PubMed          Journal:  Am J Addict        ISSN: 1055-0496


  5 in total

1.  Opioid use disorder and type 2 diabetes mellitus: Effect of participation in buprenorphine-naloxone substitution programs on glycemic control.

Authors:  Devon Tilbrook; Jeffrey Jacob; Pierre Parsons; Craig Edwards; Kassandra Loewen; Len Kelly
Journal:  Can Fam Physician       Date:  2017-07       Impact factor: 3.275

Review 2.  Substance Use Disorders among Patients with Type 2 Diabetes: a Dangerous but Understudied Combination.

Authors:  Kimberly N Walter; Julie A Wagner; Eda Cengiz; William V Tamborlane; Nancy M Petry
Journal:  Curr Diab Rep       Date:  2017-01       Impact factor: 4.810

3.  Body Composition Changes Associated With Methadone Treatment.

Authors:  Gamal E Sadek; Simon Chiu; Zack Z Cernovsky
Journal:  Int J High Risk Behav Addict       Date:  2016-02-20

4.  Similar COVID-19 incidence to the general population in people with opioid use disorder receiving integrated outpatient clinical care.

Authors:  Gabriel Vallecillo; Francina Fonseca; Lina Oviedo; Xavier Durán; Ignacio Martinez; Alexandra García-Guix; Claudio Castillo; Marta Torrens; Santiago Llana; Albert Roquer; Maria de la Cabeza Martinez; Sandra Aguelo; Irene Canosa
Journal:  Drug Alcohol Depend Rep       Date:  2022-01-15

5.  Metabolic and Addiction Indices in Patients on Opioid Agonist Medication-Assisted Treatment: A Comparison of Buprenorphine and Methadone.

Authors:  Igor Elman; Margaret Howard; Jacob T Borodovsky; David Mysels; David Rott; David Borsook; Mark Albanese
Journal:  Sci Rep       Date:  2020-03-27       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.